Ibl Healthcare LimitedPSX: IBLHL

Financial Results for the Quarter Ended Sep 30, 2025

· Issued by Ibl Healthcare Limited


CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION

AS AT SEPTEMBER 30, 2025

Un-audited Audited Note September 30, 2025

June 30,

2025

-------(Rupees in '000)-------

ASSETS

Non-current assets

Furniture and equipment

4

21,G47

20,565

Right-of-use asset

20,878

21,499

Investment properties

587,374

587,374

Intangible assets

1,412

1,600

Deferred taxation - net

10,538

10,538

642,14G

641,576

Current assets

Inventories

1,15G,358

1,270,130

Trade and other receivables

5

2,208,846

1,696,496

Loans, advances, deposits and prepayments

6

134,225

107,819

Refunds due from Government - sales tax

10,016

42,924

Taxation - payments less provision

10,277

42,085

Cash and bank balances

7

24,031

208,938

3,546,753

3,368,392

Total assets

4,188,G02

4,009,968

EǪUITY AND LIABILITIES

Share capital and reserves

Share Capital

Issued, subscribed and paid-up share capital

8

856,748

856,748

Capital reserve

Share premium

11G,600

119,600

Revenue reserve

Un-appropriated profit

1,416,3G0

1,346,702

2,3G2,738

2,323,050

Liabilities

Non-current liabilities

Lease liability

1G,075

19,887

Current liabilities

1G,075

19,887

Trade and other payables

G

1,2G3,630

1,466,510

Advance from customers

24,705

40,347

Short term borrowings

434,682

136,355

Current portion of lease liability

3,005

2,738

Unclaimed dividend

7,044

7,057

Unpaid dividend

14,022

14,024

Contingencies and commitments

10

1,777,088

1,667,031

Total equity and liabilities

4,188,G02

4,009,968

The annexed notes 1 to 14 form an integral part of this condensed interim financial statements.



Chief Executive Officer Director Chief Financial Officer


CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (Un-audited) FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2025 September 30, September 30,

Note

2025

2024

-------(Rupees in '000)-------

Revenue

11

1,120,G18

1,078,954

Cost of Sales

(720,82G)

(739,070)

Gross Profit

400,08G

339,884

Distribution costs

(230,133)

(185,174)

Administrative expenses

(3G,818)

(34,206)

Other income / (loss)

12

2,184

(1,592)

Profit from operations

132,322

118,912

Finance cost

(G,1G5)

(12,389)

Profit before levies and income tax

123,127

106,523

Levies - minimum tax

Profit before taxation

Income Tax Expense

(8,4G8)

114,62G

(44,G41)

(7,246)

GG,277

(39,413)

Profit after taxation

Other comprehensive income

6G,688

-

59,864

-

Total comprehensive income

6G,688

59,864

Earnings per share (Rupees) 0.81 0.70

The annexed notes 1 to 14 form an integral part of this condensed interim financial statements.



Chief Executive Officer Director Chief Financial Officer


CONDENSED INTERIM STATEMENT OF CHANGES IN EǪUITY (Un-audited)

FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2025

Issued,

Reserve for

subscribed

issue of

Share

Unappropriated

Total share

and paid-up

bonus

Premium

profit

holders' equity

share capital

shares

-------------------------------------(Rupees in '000)-------------------------------------

Balance as at July 01, 2024 856,748 - 119,600 1,138,331 2,114,679

Total comprehensive income for the period

ended September 30, 2024 - - - 59,864 59,864

Balance as at September 30, 2024 856,748 - 119,600 1,198,195 2,174,543

Balance as at July 01, 2025 856,748 - 119,600 1,346,702 2,323,050

Total comprehensive income for the period

ended September 30, 2025 - - - 6G,688 6G,688

Balance as at September 30, 2025 856,748 - 11G,600 1,416,3G0 2,3G2,738

The annexed notes 1 to 14 form an integral part of this condensed interim financial statements.



Chief Executive Officer Director Chief Financial Officer CONDENSED INTERIM STATEMENT OF CASH FLOWS (Un-audited) FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2025


September September Note 30, 2025 30, 2024 -------(Rupees in '000)------- CASH FLOWS FROM OPERATING ACTIVITIES

Profit before taxation 123,127 106,524

Adjustments for non-cash items:

Depreciation 1,340 445

Depreciation of right-of-use asset 621 823

Amortization of intangible assets 18G 255

Finance cost G,1G5 12,389

134,472 120,436 Decrease/(Increase) in working capital

(121,255)

(442,827)

(42,194)

-4,286

(156,717)

18,362

110,772

(512,350)

(26,406) 32,G08

-(168,847)

(15,642)

Inventories

Trade and other receivables

Loans, advances, deposits and prepayments Refund Due from Government - Sales Tax Sales tax due to Govt

Trade and other payables Advance from customers

(57G,565) (740,345) Cash (used in) / generated from operations (445,0G3) (619,909)

Income tax and levies paid (21,632) (52,621) Finance cost paid (12,533) (6,889) Net cash (used in) / generated from operating activities (47G,258) (679,419)

CASH FLOWS FROM INVESTING ACTIVITIES

Payments for acquisition of furniture and equipment

(2,722)

(719)

Net cash (used) in investing activities

(2,722)

(719)

CASH FLOWS FROM FINANCING ACTIVITIES

Dividend paid

(15)

(163)

Long-term loan obtained

1,338,538

1,200,937

Long-term loan repayment

(1,040,211)

(802,217)

Payments against lease liability

(1,23G)

(1,064)

Net cash (used) in financing activities

2G7,073

397,493

Net (decrease) /increase in cash and cash equivalents

(184,G07)

(282,645)

Cash and cash equivalents at the beginning of the period

208,G38

375,594

Cash and cash equivalents at the end of the period

24,031

92,949

The annexed notes 1 to 14 form an integral part of this condensed interim financial statements.



Chief Executive Officer Director Chief Financial Officer

Earlier from Ibl Healthcare

All Ibl Healthcare news releases